stoxline Quote Chart Rank Option Currency Glossary
  
Prothena Corporation plc (PRTA)
24.77  -0.39 (-1.55%)    03-28 16:00
Open: 25.25
High: 25.34
Volume: 773,086
  
Pre. Close: 25.16
Low: 24.29
Market Cap: 1,331(M)
Technical analysis
2024-03-28 4:53:42 PM
Short term     
Mid term     
Targets 6-month :  33.23 1-year :  36.24
Resists First :  28.45 Second :  31.03
Pivot price 26.28
Supports First :  24.29 Second :  20.2
MAs MA(5) :  25.2 MA(20) :  26.9
MA(100) :  32.04 MA(250) :  48.12
MACD MACD :  -1.1 Signal :  -1
%K %D K(14,3) :  7.5 D(3) :  10.5
RSI RSI(14): 38.3
52-week High :  79.65 Low :  24.28
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PRTA ] has closed above bottom band by 25.7%. Bollinger Bands are 16.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 25.37 - 25.5 25.5 - 25.62
Low: 23.93 - 24.08 24.08 - 24.23
Close: 24.48 - 24.73 24.73 - 24.97
Company Description

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

Headline News

Wed, 27 Mar 2024
Prothena (PRTA) Alzheimer's Disease Drug Licensed by BMY - Yahoo Movies Canada

Mon, 25 Mar 2024
SG Americas Securities LLC Has $4.94 Million Holdings in Prothena Co. plc (NASDAQ:PRTA) - MarketBeat

Mon, 25 Mar 2024
SG Americas Securities LLC Acquires 43363 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World

Fri, 23 Feb 2024
Prothena: Alzheimer's Data Update In 2024 Could Move The Needle (NASDAQ:PRTA) - Seeking Alpha

Fri, 16 Feb 2024
Prothena Corporation plc (NASDAQ:PRTA) Q4 2023 Earnings Call Transcript - Yahoo Finance

Thu, 08 Feb 2024
Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024 - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 54 (M)
Held by Insiders 3.828e+007 (%)
Held by Institutions 12.4 (%)
Shares Short 5,750 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.9011e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin -161 %
Operating Margin -24 %
Return on Assets (ttm) 846.5 %
Return on Equity (ttm) -16.5 %
Qtrly Rev. Growth 9.137e+007 %
Gross Profit (p.s.) -451.82
Sales Per Share -112.96
EBITDA (p.s.) 0
Qtrly Earnings Growth -2.8 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -134 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio -0.2
Price to Book value 0
Price to Sales -0.22
Price to Cash Flow 0.52
Stock Dividends
Dividend 0
Forward Dividend 6.07e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android